In a phase III clinical trial, interleukin 13-pseudomonas toxin administered via CED showed similar survival in adult glioblastoma (GBM) patients at first recurrence compared to the Gliadel® wafer, the only long-acting GBM treatment approved by the U.S. FDA [37]. This evidence concerns the gene IL13 and glioblastoma.